Share-based Payment Arrangement, Expense of AbbVie Inc. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
AbbVie Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • AbbVie Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $209,000,000, a 15% increase year-over-year.
  • AbbVie Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $962,000,000, a 10% increase year-over-year.
  • AbbVie Inc. annual Share-based Payment Arrangement, Expense for 2024 was $911,000,000, a 22% increase from 2023.
  • AbbVie Inc. annual Share-based Payment Arrangement, Expense for 2023 was $747,000,000, a 11% increase from 2022.
  • AbbVie Inc. annual Share-based Payment Arrangement, Expense for 2022 was $671,000,000, a 3% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

AbbVie Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $962,000,000 $209,000,000 +$28,000,000 +15% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $934,000,000 $179,000,000 -$39,000,000 -18% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $973,000,000 $410,000,000 +$62,000,000 +18% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $911,000,000 $164,000,000 +$39,000,000 +31% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
Q3 2024 $872,000,000 $181,000,000 +$51,000,000 +39% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $821,000,000 $218,000,000 +$39,000,000 +22% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $782,000,000 $348,000,000 +$35,000,000 +11% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $747,000,000 $125,000,000 -$7,000,000 -5.3% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
Q3 2023 $754,000,000 $130,000,000 +$4,000,000 +3.2% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $750,000,000 $179,000,000 +$72,000,000 +67% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $678,000,000 $313,000,000 +$7,000,000 +2.3% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $671,000,000 $132,000,000 +$3,000,000 +2.3% 01 Oct 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
Q3 2022 $668,000,000 $126,000,000 -$9,000,000 -6.7% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $677,000,000 $107,000,000 -$52,000,000 -33% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $729,000,000 $306,000,000 +$37,000,000 +14% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $692,000,000 $129,000,000 -$7,000,000 -5.1% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $699,000,000 $135,000,000 -$27,000,000 -17% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2022 Q3
Q2 2021 $726,000,000 $159,000,000 -$77,000,000 -33% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $803,000,000 $269,000,000 +$50,000,000 +23% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $753,000,000 $136,000,000 +$57,000,000 +72% 01 Oct 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
Q3 2020 $696,000,000 $162,000,000 +$87,000,000 +116% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $609,000,000 $236,000,000 +$149,000,000 +171% 01 Apr 2020 30 Jun 2020 10-Q 02 Aug 2021 2021 Q2
Q1 2020 $460,000,000 $219,000,000 +$30,000,000 +16% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $430,000,000 $79,000,000 +$9,000,000 +13% 01 Oct 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
Q3 2019 $421,000,000 $75,000,000 $0 0% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $421,000,000 $87,000,000 +$2,000,000 +2.4% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $419,000,000 $189,000,000 -$2,000,000 -1% 01 Jan 2019 31 Mar 2019 10-Q 08 May 2020 2020 Q1
Q4 2018 $421,000,000 $70,000,000 -$7,000,000 -9.1% 01 Oct 2018 31 Dec 2018 10-K 19 Feb 2021 2020 FY
Q3 2018 $428,000,000 $75,000,000 +$4,000,000 +5.6% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $424,000,000 $85,000,000 +$9,000,000 +12% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2
Q1 2018 $415,000,000 $191,000,000 +$50,000,000 +35% 01 Jan 2018 31 Mar 2018 10-Q 03 May 2019 2019 Q1
Q4 2017 $365,000,000 $77,000,000 +$3,000,000 +4.1% 01 Oct 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
Q3 2017 $362,000,000 $71,000,000 +$24,000,000 +51% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $338,000,000 $76,000,000 -$61,000,000 -45% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $399,000,000 $141,000,000 +$3,000,000 +2.2% 01 Jan 2017 31 Mar 2017 10-Q 04 May 2018 2018 Q1
Q4 2016 $396,000,000 $74,000,000 +$21,000,000 +40% 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $375,000,000 $47,000,000 -$8,000,000 -15% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $383,000,000 $137,000,000 +$82,000,000 +149% 01 Apr 2016 30 Jun 2016 10-Q 07 Aug 2017 2017 Q2
Q1 2016 $301,000,000 $138,000,000 +$19,000,000 +16% 01 Jan 2016 31 Mar 2016 10-Q 05 May 2017 2017 Q1
Q4 2015 $282,000,000 $53,000,000 +$11,000,000 +26% 01 Oct 2015 31 Dec 2015 10-K 16 Feb 2018 2017 FY
Q3 2015 $271,000,000 $55,000,000 +$11,000,000 +25% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $260,000,000 $55,000,000 +$6,000,000 +12% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2016 2016 Q2
Q1 2015 $254,000,000 $119,000,000 +$13,000,000 +12% 01 Jan 2015 31 Mar 2015 10-Q 06 May 2016 2016 Q1
Q4 2014 $241,000,000 $42,000,000 +$4,000,000 +11% 01 Oct 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
Q3 2014 $237,000,000 $44,000,000 +$3,000,000 +7.3% 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015 2015 Q3
Q2 2014 $234,000,000 $49,000,000 +$3,000,000 +6.5% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015 2015 Q2
Q1 2014 $231,000,000 $106,000,000 +$19,000,000 +22% 01 Jan 2014 31 Mar 2014 10-Q 08 May 2015 2015 Q1
Q4 2013 $212,000,000 $38,000,000 +$7,000,000 +23% 01 Oct 2013 31 Dec 2013 10-K 19 Feb 2016 2015 FY
Q3 2013 $205,000,000 $41,000,000 +$11,000,000 +37% 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014 2014 Q3
Q2 2013 $194,000,000 $46,000,000 +$11,000,000 +31% 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $183,000,000 $87,000,000 -$4,000,000 -4.4% 01 Jan 2013 31 Mar 2013 10-Q 09 May 2014 2014 Q1
Q4 2012 $187,000,000 $31,000,000 01 Oct 2012 31 Dec 2012 10-K 20 Feb 2015 2014 FY
Q3 2012 $30,000,000 01 Jul 2012 30 Sep 2012 10-Q 12 Nov 2013 2013 Q3
Q2 2012 $35,000,000 01 Apr 2012 30 Jun 2012 10-Q 09 Aug 2013 2013 Q2
Q1 2012 $91,000,000 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1

AbbVie Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $911,000,000 +$164,000,000 +22% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025 2024 FY
2023 $747,000,000 +$76,000,000 +11% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025 2024 FY
2022 $671,000,000 -$21,000,000 -3% 01 Jan 2022 31 Dec 2022 10-K 14 Feb 2025 2024 FY
2021 $692,000,000 -$61,000,000 -8.1% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $753,000,000 +$323,000,000 +75% 01 Jan 2020 31 Dec 2020 10-K 17 Feb 2023 2022 FY
2019 $430,000,000 +$9,000,000 +2.1% 01 Jan 2019 31 Dec 2019 10-K 18 Feb 2022 2021 FY
2018 $421,000,000 +$56,000,000 +15% 01 Jan 2018 31 Dec 2018 10-K 19 Feb 2021 2020 FY
2017 $365,000,000 -$31,000,000 -7.8% 01 Jan 2017 31 Dec 2017 10-K 21 Feb 2020 2019 FY
2016 $396,000,000 +$114,000,000 +40% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $282,000,000 +$41,000,000 +17% 01 Jan 2015 31 Dec 2015 10-K 16 Feb 2018 2017 FY
2014 $241,000,000 +$29,000,000 +14% 01 Jan 2014 31 Dec 2014 10-K 17 Feb 2017 2016 FY
2013 $212,000,000 +$25,000,000 +13% 01 Jan 2013 31 Dec 2013 10-K 19 Feb 2016 2015 FY
2012 $187,000,000 +$24,000,000 +15% 01 Jan 2012 31 Dec 2012 10-K 20 Feb 2015 2014 FY
2011 $163,000,000 01 Jan 2011 31 Dec 2011 10-K 21 Feb 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.